Sharing Clinical Research Data

Workshop Summary

AvInstitute of Medicine,Board on Health Care Services

Häftad, Engelska, 2013

510 kr

Tillfälligt slut

Beskrivning

Pharmaceutical companies, academic researchers, and government agencies such as the Food and Drug Administration and the National Institutes of Health all possess large quantities of clinical research data. If these data were shared more widely within and across sectors, the resulting research advances derived from data pooling and analysis could improve public health, enhance patient safety, and spur drug development. Data sharing can also increase public trust in clinical trials and conclusions derived from them by lending transparency to the clinical research process. Much of this information, however, is never shared. Retention of clinical research data by investigators and within organizations may represent lost opportunities in biomedical research. Despite the potential benefits that could be accrued from pooling and analysis of shared data, barriers to data sharing faced by researchers in industry include concerns about data mining, erroneous secondary analyses of data, and unwarranted litigation, as well as a desire to protect confidential commercial information.Academic partners face significant cultural barriers to sharing data and participating in longer term collaborative efforts that stem from a desire to protect intellectual autonomy and a career advancement system built on priority of publication and citation requirements. Some barriers, like the need to protect patient privacy, pre- sent challenges for both sectors. Looking ahead, there are also a number of technical challenges to be faced in analyzing potentially large and heterogeneous datasets. This public workshop focused on strategies to facilitate sharing of clinical research data in order to advance scientific knowledge and public health. While the workshop focused on sharing of data from preplanned interventional studies of human subjects, models and projects involving sharing of other clinical data types were considered to the extent that they provided lessons learned and best practices. The workshop objectives were to examine the benefits of sharing of clinical research data from all sectors and among these sectors, including, for example: benefits to the research and development enterprise and benefits to the analysis of safety and efficacy.Sharing Clinical Research Data: Workshop Summary identifies barriers and challenges to sharing clinical research data, explores strategies to address these barriers and challenges, including identifying priority actions and "low-hanging fruit" opportunities, and discusses strategies for using these potentially large datasets to facilitate scientific and public health advances.

Produktinformation

Utforska kategorier

Innehållsförteckning

Hoppa över listan

Mer från samma författare

Scientific Communication and National Security

National Academy of Engineering, National Academy of Sciences, Policy and Global Affairs, Institute of Medicine, and Public Policy Committee on Science, Engineering, Panel on Scientific Communication and National Security

Häftad

704 kr

Bereavement

Institute of Medicine, Committee for the Study of Health Consequences of the Stress of Bereavement

Häftad

967 kr

Preventing Low Birthweight

Institute of Medicine, Division of Health Promotion and Disease Prevention, Committee to Study the Prevention of Low Birthweight

Häftad

690 kr

Preventing Low Birthweight

Institute of Medicine, Division of Health Promotion and Disease Prevention, Committee to Study the Prevention of Low Birthweight

Häftad

238 kr

Assessing Medical Technologies

Institute of Medicine, Division of Health Promotion and Disease Prevention, Division of Health Sciences Policy, Committee for Evaluating Medical Technologies in Clinical Use

Inbunden

1 068 kr

New Vaccine Development

Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health

Häftad

785 kr

Hoppa över listan

Mer från samma serie

Challenges for the FDA

Institute of Medicine, Board on Health Sciences Policy, and Translation Forum on Drug Discovery, Development

Häftad

526 kr

Breakthrough Business Models

Institute of Medicine, Board on Health Sciences Policy, and Translation Forum on Drug Discovery, Development, Robert Giffin, Sally Robinson, Theresa Wizemann

Häftad

594 kr

Hoppa över listan

Du kanske också är intresserad av

Deriving Drug Discovery Value from Large-Scale Genetic Bioresources

and Medicine National Academies of Sciences, Engineering, Health and Medicine Division, Board on Health Sciences Policy, and Translation Forum on Drug Discovery, Development, Roundtable on Genomics and Precision Health, Sarah H. Beachy, Steve Olson, Amanda Wagner Gee, Siobhan Addie

Häftad

546 kr

Sharing Clinical Trial Data

Institute of Medicine, Board on Health Sciences Policy, Committee on Strategies for Responsible Sharing of Clinical Trial Data

Häftad

785 kr

Ovarian Cancers

and Medicine National Academies of Sciences, Engineering, Institute of Medicine, Board on Health Care Services, Committee on the State of the Science in Ovarian Cancer Research

Häftad

905 kr

Biomarker Tests for Molecularly Targeted Therapies

and Medicine National Academies of Sciences, Engineering, Institute of Medicine, Board on Health Care Services, Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies, Harold L. Moses, Jonathan K. Phillips, Laurene A. Graig

Häftad

749 kr

Challenges for the FDA

Institute of Medicine, Board on Health Sciences Policy, and Translation Forum on Drug Discovery, Development

Häftad

526 kr